Navigation Links
Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
Date:4/30/2013

GENEVA, April 30, 2013 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that it has closed an agreement with Ligand Pharmaceuticals Incorporated to sell potential milestone and royalty payments for more than 15 biologic development programs from Selexis.  

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO)

The acquired programs are in various preclinical and clinical stages. Funds from the Ligand deal will be used for R&D to further develop the next generation of SUREtechnology Platform™ products. Torreya Partners acted as financial advisor to Selexis. Selexis currently holds milestone and potential royalty interest payment rights to an additional 14 biologic development programs not included in the Ligand deal.

"With this truly innovative financing solution, Selexis was able to leverage a percentage of potential future revenues to fund, reinforce and expand our SUREtechnology Platform," said Dr. Igor Fisch , CEO, Selexis SA. "The non-diluting funds will support the growth of our products and technologies faster. The Company's SUREtechnology Platform is a powerful engine that continues to fuel royalty opportunities for Selexis." 

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Contact:
Robert Meister
602-953-1716 
robert.meister@selexis.com


'/>"/>
SOURCE Selexis SA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selexis Announces Expansion of R&D License Agreement with Amgen
2. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
3. Microsofts Surface Pro Tablet Makes its Debut and Sells Out Fast; the Company was One of the Few to Defy the Dows Loss Yesterday
4. Cerecor Acquires Rights to NR2B Receptor Antagonist from Merck
5. Nephros Announces Rights Offering and Temporary Reduction in Exercise Price for March 2011 Warrants
6. Cerecor Acquires Rights to Merck COMT Inhibitors
7. Topokine Acquires Exclusive Rights to Revolutionary Technology for Manufacturing Topical Fat-Reducing Medications
8. Joe Gibbs Racing, BrightSky Launch Defy Diabetes Movement
9. Americans United for Life Celebrates Win for Illinois Conscience Rights in Case AUL Championed Since 2005
10. China Biologic Products, Inc. Adopts Stockholder Rights Plan
11. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... 2017  As the specialty pharmacy industry and ... make the revolutionary shift from volume-based to value-based ... positive patient outcomes and shaping the future of ... away from clinical trials and toward data that ... drug therapy utilization in precise patient populations. Therigy ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... “When the Stars ... Home” is the creation of published author Laura Weigel Douglas, an avid reader who ... in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t be ...
(Date:5/26/2017)... ... 2017 , ... Centennial-based BluSky Restoration Contractors announced that The ... Clays for Kids fundraiser, to be held Friday, Sept. 22, at Kiowa Creek ... of BluSky’s partnership with The Adoption Exchange, BluSky will also share sponsorship with ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Cactus Jack: Against ... on so many others. “Cactus Jack: Against All Odds” is the creation of ... Walter D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last month, representatives from ... employees, and town officials to celebrate the grand opening of the 87,000 square ... as part of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest health ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
Breaking Medicine News(10 mins):